OCMS Bio Appoints Pavel Nikitin as Chief Development Officer to Drive Preclinical Pipeline
Dr. Nikitin bringing extensive experience in biopharmaceutical development.
OCMS Bio Selected to Present at Biotech Showcase JPM 2025
The company’s selection at Biotech Showcase provides a powerful platform to showcase its latest advancements.
OCMS Bio Showcases AI-Driven Antibody Discovery at Antibody Engineering & Therapeutics 2024
Dr. Ramdev Puligedda presented groundbreaking research at Antibody Engineering & Therapeutics 2024, highlighting the company’s innovative use of artificial intelligence (AI) in monoclonal antibody discovery.
OCMS Bio Expands Operations with New Facility at 3700 Horizon Drive
OCMS Bio's expansion to a new state-of-the-art facility in King of Prussia boosts our antibody research and preclinical pipeline.
